Control-IQ™ Technology: See how easy control can be.
Predicts and helps prevent both highs and lows to help increase time in range.*
*as measured by CGM
Making Diabetes Easier with Control-IQ Technology
Trying to keep your blood glucose in range can be stressful. Our Control-IQ™ Advanced Hybrid Closed-loop Technology makes it easier by using Dexcom G6 CGM values to predict glucose levels 30 minutes in the future and automatically adjusting insulin to help increase time in range.*
*As measured by CGM
Key features
Advanced predictive technology
helps prevent both hyperglycaemia and hypoglycaemia to increase Time in Range (3.9 to 10 mmol/L)* by using the Dexcom G6 CGM values to predict glucose levels 30 minutes in the future and adjust insulin delivery accordingly.
Automatic correction Bolus
up to 1 per hour for optimal protection.
Features Sleep and Exercise Activities
Control-IQ Technology includes optional Sleep and Exercise Activities settings that adjust treatment ranges for more control.
Disclaimer: *If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose metre to make diabetes treatment decisions.
How does it work?
Control-IQ Technology predicts glucose values 30 minutes in the future, based on Dexcom G6 CGM readings, and can decrease or stop basal insulin delivery to help prevent lows or increase basal insulin delivery and provide automatic correction boluses to help avoid highs.
Clinical Study Results
More time in range
Average additional time per day that Control-IQ Technology participants spent in range* compared to Sensor Augmented Pumps
Easy to use
Percent of study participants who used Control-IQ Technology and said it was easy to use.
References
[1]. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomised crossover study: Results of the PROLOG trial. Diabetes Care. 2019;41(10):2155-2161.
[2]. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomised, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707-1717.
[3]. Brown, S. Clinical acceptance of the artificial pancreas: Glycemia outcomes
from a 6-month multicenter RCT. 2019 ADA 79th Scientific Sessions, San Francisco, CA.
Tandem Important Safety Information
1. If your glucose alerts and CGM readings do not match your symptoms and expectations, you should perform a fingerstick to confirm your blood glucose level.
2. If glucose values are predicted to be above 10.0 mmol/L, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 6.1 mmol/L and delivers 60% of that value. An Automatic Correction Bolus will not occur within 60 minutes of a bolus that has been delivered or cancelled.
3. Software updates are only available to customers who are in warranty at the time they update their pump, and may require additional training.
4. Dexcom CGM sold separately. Transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 insulin pump) and one consumer device (phone or tablet) at the same time.
5. Control-IQ Technology is not a substitute for active self-management of your diabetes.
